Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: A comparative study

Contraception

Volumn 69, Issue 5, 2004, Pages 407-412

  Suhonen, Satu ^a   Haukkamaa, Maija ^a   Jakobsson, Tell ^b   Rauramo, Ilkka ^c,d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Oy Leiras Finland Ab   (Finland)

^d Finska Lo karforeningen Duodecim   (Finland)

Author keywords

Contraception; Intrauterine system; Nulliparous women

Indexed keywords

HORMONE; LEVONORGESTREL;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; FAMILY; FEMALE; HUMAN; MENSTRUATION; NULLIPARA; OBSERVATION; ORAL CONTRACEPTION; OUTPATIENT DEPARTMENT; PAIN; POPULATION RESEARCH; QUESTIONNAIRE; SEXUAL BEHAVIOR; UNIVERSITY HOSPITAL; WELLBEING;

ADOLESCENT; ADULT; AMBULATORY CARE FACILITIES; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; FINLAND; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; PARITY; PATIENT SATISFACTION; QUESTIONNAIRES; SEXUAL BEHAVIOR;

EID: 1942519393     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.11.008     Document Type: Article

References (24)

1. Panser L.A., Phipps W.R. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception. 43:1991;91-99.
2. Grodstein F., Rothman K.J. Epidemiology of pelvic inflammatory disease. Epidemiology. 5:1994;234-242.
3. Luukkainen T., Nielsen N.-C., Nygren K.-G., Pyörälä T. Nulliparous women, IUD and pelvic infection. Ann Clin Res. 11:1979;121-124.
4. Diaz J., Pinto Neto A.M., Bahamondes L., Diaz M., Arce X.E., Castro S. Performance of copper T 200 in parous adolescents are copper IUDs suitable for these women? Contraception. 48:1993;23-28.
5. Toivonen J., Luukkainen T., Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection three years′ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol. 77:1991;261-264.
6. Andersson K., Odlind V., Rybo G. Levonorgestrel releasing and copper releasing (Nova T) IUDs during five years of use. A randomized comparative study. Contraception. 49:1994;56-72.
7. Milsom I., Rybo G., Lindstedt G. The influence of copper surface area on menstrual blood loss and iron status in women fitted with an IUD. Contraception. 41:1989;271-281.
8. Bergkvist A., Rybo G. Treatment of menorrhagia with intrauterine release of progesterone. Br J Obstet Gynaecol. 90:1983;255-258.
9. Milsom I., Andersson K., Andersch B., Rybo G. Comparison of flurbiprofen, tranexamic acid and a levonorgestrel-releasing intrauterine device in treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 164:1991;879-883.
10. Sivin I., Stern J., International Committee for Contraception Research. Health during prolonged use of levonorgestrel 20 μg/d and copper TCu 380Ag intrauterine contraceptive devices a multicenter study. Fertil Steril. 61:1994;70-77.
11. Suvisaari J., Lähteenmäki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of copper IUD or a levonorgestrel-releasing intrauterine system. Contraception. 54:1996;201-208.
12. Belsey E.M., Farley T.M.M. The analysis of menstrual bleeding patterns a review. Contraception. 38:1988;129-156.
13. Sivin I., El Mahgoub S., McCarthy T., et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNG 20) and the copper T 380Ag intrauterine device a five-year randomized study. Contraception. 42:1990;361-378.
14. Andersson K. Intrauterine release of levonorgestrel, a contraceptive and therapeutical system. Thesis, University of Gothenburg, Sweden, 1993
15. Luukkainen T., Allonen H., Haukkamaa M., et al. Effective contraception with the levonorgestrel-releasing intrauterine device 12-month report of a European multicenter study. Contraception. 36:1987;160-179.
16. Munday P.E. Clinical aspects of pelvic inflammatory disease. Hum Reprod. 12:(Suppl):1997;121-126.
17. Weström L. Incidence, prevalence and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol. 138:1980;880-892.
18. Hubacher D., Lara-Ricalde R., Taylor D.J., et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 345:2001;561-567.
19. Ness R.B., Keder L.M., Soper D.E., et al. Oral contraception and the recognition of endometritis. Am J Obstet Gynecol. 176:1997;580-585.
20. Henry-Suchet J., Sluzhinska A., Serfaty D. Chlamydia trachomatis screening in family-planning centers a review of cost/benefit evalutions in different countries. Eur J Contracept Reproduct Health Care. 1:1996;301-309.
21. Farley T.M.M., Rosenberg M.J., Rowe P.J., Chen J.-H., Meirik O. Intrauterine devices and pelvic inflammatory disease an international perspective. Lancet. i:1992;785-788.
22. Grimes D.A., Schulz K.F. Prophylactic antibiotics for intrauterine device insertion a meta-analysis of the randomized controlled trials. Contraception. 60:1999;57-63.
23. den Tonkelaar I., Oddens B.J. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 5:1999;357-362.
24. Rosenberg M.J., Waugh M.S. Oral contraceptive discontinuation a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 179:1998;577-582.